PD 153035 hydrochloride

Biological Activity

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Additional Information

Background References

1. Endophilin marks and controls a clathrin-independent endocytic pathway.
   Boucrot E, Ferreira A, Almeida-Souza L, Debard S, Vallis Y, Howard G, Bertot L, Sauvonnet N, McMahon H
   Nature, 2015;517(7535):460-5.
2. ADAM12 is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling
   R Roy, A Dagher, C Butterfiel, MA Moses
   Mol. Cancer Res., 2017;0(0):.
3. The Q43L mutant of neuregulin 2beta is a pan-ErbB receptor antagonist.
   Wilson KJ, Mill CP, Gallo RM, Cameron EM, VanBrocklin H, Settleman J, Riese DJ
   Biochem. J., 2012;443(1):133-44.
4. Signaling pathways induced by serine proteases to increase intestinal epithelial barrier function
   KA Lahey, NJ Ronaghan, J Shang, SP Dion, A Désilets, R Leduc, WK MacNaughto
   PLoS ONE, 2017;12(7):e0180259.
5. Epidermal Expression and Regulation of Interleukin-33 during Homeostasis and Inflammation: Strong Species Differences.
   Sundnes O, Pietka W, Loos T, Sponheim J, Rankin A, Pflanz S, Bertelsen V, Sitek J, Hol J, Haraldsen G, Khnykin D
   J Invest Dermatol, 2015;135(7):1771-80.
6. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
   Bridges et al.
   J.Med.Chem., 1996;39:267
7. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
   Bos et al.
   Clin.Cancer Res., 1997;3:2099
8. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.
   Fry et al.
   Science, 1994;265:1093

Product Datasheets